Autologous Graft-versus-Tumor Effect: Reality or Fiction?

Table 1

Survival outcomes based on absolute lymphocyte count recovery after autologous hematopoietic stem cell transplantation.

Study [reference]	Study design; (disease)	Days after AHSCT ALC obtained	ALC cut-off value (µ/L)	OS			PFS
				yrs	rates		yrs	rates
Porrata et al., 2001 [5]	Retrospective					<0.0001			<0.0001
	(non-Hodgkin’s lymphoma)	15	≥500	5	85%		5	72%
			<500	5	15%		5	0%
	Retrospective					<0.0001			<0.0003
	(multiple myeloma)	15	≥500	5	30%		5	20%
			<500	5	0%		5	0%
Porrata et al., 2001 [13]	Retrospective					<0.0001			<0.0001
	(metastatic breast cancer)	15	≥500	3	55%		3	45%
			<500	3	0%		3	0%
Porrata et al., 2002 [14]	Retrospective					<0.0001			<0.002
	(Hodgkin’s lymphoma)	15	≥500	5	80%		5	50%
			<500	5	30%		5	20%
Porrata et al., 2002 [15]	Retrospective					<0.0009			<0.0008
	(acute myelogenous leukemia)	15	≥500	5	68%		5	66%
			<500	5	19%		5	5%
Ferrandina et al., 2003 [16]	Retrospective					<0.0015			<0.0026
	(ovarian cancer)	365	≥850	3	93%		3	86%
			<850	3	62%		3	23%
Gordan et al., 2003 [17]	Retrospective					0.27			<0.02
	(Hodgkin’s and non-Hodgkin’s lymphoma)	15	≥667	5	70%		5	55%
			<667	5	60%		5	25%
Nieto et al., 2004 [18]	Retrospective					<0.04			<0.007
	(metastatic breast cancer)	15	≥500	5	42%		5	58%
			<500	5	29%		5	18%
Kim et al., 2004 [19]	Retrospective					<0.005			<0.011
	(T-cell non-Hodgkin’s lymphoma)	25	≥1000	5	48%		5	80%
			<1000	5	18%		5	30%
Porrata et al., 2005 [20]	Retrospective					<0.0003			<0.0001
	(systemic amyloidosis)	15	≥500	5	95%		5	80%
			<500	5	40%		5	30%
Kim et al., 2006 [21]	Retrospective					<0.0156			<0.0243
	(multiple myeloma)	23	≥1000	5	50%		5	35%
			<1000	5	27%		5	10%
Boulassel et al., 2006 [22]	Retrospective					<0.001			<0.001
	(Lymphoproliferative disorders)	15	≥500	3	91%		5	70%
			<500	3	68%		5	20%
Joao et al., 2006 [23]	Retrospective					<0.01			<0.0006
	(mantle cell lymphoma)	15	≥500	5	70%		5	70%
			<500	5	25%		5	5%
Porrata et al., 2008 [6]	Prospective					<0.0001			<0.0001
	(non-Hodgkin’s lymphoma)	15	≥500	5	80%		5	63%
			<500	5	37%		5	13%
Valtola et al., 2016 [7]	Prospective				<0.002				<0.015
	(non-Hodgkin’s lymphoma)	15	≥500	3	88%		3	80%
			<500	3	30%		3	38%

This number is based on the CD3 count. ALC: absolute lymphocyte count; AHSCT: autologous hematopoietic stem cell transplantation; yrs: years.